Jeannette Potts Sells 4,670 Shares of uniQure N.V. (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE - Get Free Report) insider Jeannette Potts sold 4,670 shares of the firm's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $15.14, for a total value of $70,703.80. Following the completion of the transaction, the insider now owns 115,073 shares of the company's stock, valued at $1,742,205.22. The trade was a 3.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

uniQure Stock Performance

Shares of QURE stock traded down $0.26 during midday trading on Monday, hitting $13.95. 1,978,275 shares of the company were exchanged, compared to its average volume of 1,952,298. uniQure N.V. has a 52 week low of $3.73 and a 52 week high of $19.18. The firm has a market capitalization of $764.18 million, a P/E ratio of -3.18 and a beta of 0.08. The firm's 50 day moving average price is $14.20 and its two-hundred day moving average price is $13.94. The company has a debt-to-equity ratio of 1.53, a quick ratio of 11.99 and a current ratio of 11.99.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative return on equity of 483.87% and a negative net margin of 1,077.05%. As a group, equities research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current year.

Wall Street Analyst Weigh In

QURE has been the subject of a number of analyst reports. Chardan Capital restated a "buy" rating and issued a $38.00 price target on shares of uniQure in a research note on Friday, May 30th. Wells Fargo & Company cut their price objective on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Cantor Fitzgerald upgraded shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Wall Street Zen lowered shares of uniQure from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price objective on shares of uniQure in a research report on Monday, May 12th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, uniQure has a consensus rating of "Moderate Buy" and an average target price of $37.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in QURE. Woodline Partners LP grew its position in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock worth $1,864,000 after purchasing an additional 35,175 shares in the last quarter. 683 Capital Management LLC grew its position in uniQure by 1.6% during the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company's stock worth $16,430,000 after buying an additional 25,000 shares in the last quarter. Vestal Point Capital LP increased its stake in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after acquiring an additional 1,767,572 shares during the period. Birchview Capital LP increased its stake in uniQure by 343.5% during the 1st quarter. Birchview Capital LP now owns 88,697 shares of the biotechnology company's stock worth $940,000 after acquiring an additional 68,697 shares during the period. Finally, Nantahala Capital Management LLC raised its holdings in uniQure by 3.8% in the 1st quarter. Nantahala Capital Management LLC now owns 2,755,962 shares of the biotechnology company's stock valued at $29,213,000 after acquiring an additional 101,598 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.